BioCryst Pharmaceuticals
BCRX
#4414
Rank
ยฃ1.77 B
Marketcap
ยฃ7.08
Share price
-1.47%
Change (1 day)
27.32%
Change (1 year)

Operating Margin for BioCryst Pharmaceuticals (BCRX)

Operating Margin as of April 2026 (TTM): 30.56%

According to BioCryst Pharmaceuticals 's latest financial reports and stock price the company's current Operating Margin is 30.56%. At the end of 2025 the company had an Operating Margin of 30.56%.

Operating Margin history for BioCryst Pharmaceuticals from 2001 to 2025

Operating Margin at the end of each year

Year Operating Margin Change
202530.56%-258.43%
2024-19.29%-71.74%
2023-68.26%-24.35%
2022-90.24%-21.99%
2021-115.68%-88.73%
2020-1,026.35%360.27%
2019-222.99%-54.52%
2018-490.25%87.7%
2017-261.18%24.82%
2016-209.25%134.73%
2015-89.15%-73.16%
2014-332.08%91.15%
2013-173.72%16.88%
2012-148.64%-48.73%
2011-289.91%434.23%
2010-54.27%194.66%
2009-18.42%-61.65%
2008-48.03%5.99%
2007-45.31%-94.01%
2006-756.28%-95.77%
2005-17,895.15%177.17%
2004-6,456.46%208.3%
2003-2,094.18%98.69%
2002-1,053.98%2258.83%
2001-44.68%

Operating Margin for similar companies or competitors

Company Operating Margin Operating Margin differencediff. Country
Gilead Sciences
GILD
33.27% 8.87%๐Ÿ‡บ๐Ÿ‡ธ USA
GSK plc
GSK
22.60%-26.05%๐Ÿ‡ฌ๐Ÿ‡ง UK
Sarepta Therapeutics
SRPT
-30.20%-198.82%๐Ÿ‡บ๐Ÿ‡ธ USA
Repligen
RGEN
8.45%-72.35%๐Ÿ‡บ๐Ÿ‡ธ USA
Novavax
NVAX
-25.89%-184.72%๐Ÿ‡บ๐Ÿ‡ธ USA
Celldex Therapeutics
CLDX
-16,748.00%-54,903.66%๐Ÿ‡บ๐Ÿ‡ธ USA
NanoViricides
NNVC
0.00%N/A๐Ÿ‡บ๐Ÿ‡ธ USA
Cel-Sci
CVM
-388.94%-1,372.71%๐Ÿ‡บ๐Ÿ‡ธ USA
Emergent BioSolutions
EBS
-14.09%-146.11%๐Ÿ‡บ๐Ÿ‡ธ USA

What is a company's Operating Margin?

The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.